91774 Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices 

Human Services, is contemplating the 

grant of an exclusive, sublicensable 

patent license to The Trustees of 

Columbia University in the City of New 

York, Columbia Technology Ventures, 

located in New York, New York to 

practice the inventions embodied in the 

patent applications listed in the 

SUPPLEMENTARY INFORMATION section of 

this notice. 

DATES: Only written comments and/or 

applications for a license which are 

received by the Technology Transfer 

and Intellectual Property Office, 

National Institute of Allergy and 

Infectious Diseases on or before 

December 5, 2024 will be considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

exclusive patent license should be 

directed to: Wade Green, Ph.D., Lead 

Technology Transfer and Patent 

Specialist, Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, 5601 Fishers Lane, Suite 2G, 

MSC9804, Rockville, MD 20852–9804, 

phone number 301–761–7505, or 

wade.green@nih.gov. 

SUPPLEMENTARY INFORMATION: The 

following represents the intellectual 

property to be licensed under the 

prospective agreement: U.S. Provisional 

Patent Application Serial No. 68/ 

428,826, filed November 30, 2022, titled 

‘‘Peptides And Peptide Microarrays For 

Detection And Differentiation Of 

Antibody Responses To Ebola Virus 

And Other Pathogens’’ (HHS Reference 

No. E–028–2024–0–US–01) and 

International Patent Application No. 

PCT/US23/81625, filed on November 

29, 2023, titled ‘‘Peptides And Peptide 

Microarrays For Detection And 

Differentiation Of Antibody Responses 

To Ebola Virus’’ (HHS Reference No. E– 

028–2024–0–PC–01). All rights in these 

inventions have been assigned to The 

Trustees of Columbia University in the 

City of New York, Columbia Technology 

Ventures and the Government of the 

United States of America. 

The prospective patent license will be 

for the purpose of consolidating the 

patent rights with The Trustees of 

Columbia University in the City of New 

York, Columbia Technology Ventures, 

the co-owner of said rights, for 

commercial development and 

marketing. Consolidation of these coowned rights is intended to expedite 

development of the invention, 

consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212. 

The prospective interinstitutional 

agreement will include an exclusive 

license for NIAID’s rights in these 

jointly owned patents. It will be 

sublicensable, and any sublicenses 

granted by The Trustees of Columbia 

University in the City of New York 

Columbia Technology Ventures will be 

subject to the provisions of 37 CFR part 

404. 

The subject patent rights are related to 

novel peptides that enable specific and 

sensitive serological detection of 

adaptive immune responses to a wide 

range of clinically important high threat 

pathogens circulating in sub-Saharan 

Africa on a wide range of platforms. 

These assays allow identification of 

individuals who have been immunized 

and/or infected with filoviruses. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and may be granted 

unless within fifteen (15) days from the 

date of this published notice, the 

National Insitute of Allergy and 

Infectious Diseases receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: November 15, 2024. 

Jeremiah D. Mitzelfelt, 

Acting Deputy Director, Technology Transfer 

and Intellectual Property Office, National 

Institute of Allergy and Infectious Diseases. 

[FR Doc. 2024–27096 Filed 11–19–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; Tissue Chips in Space 2.0. 

Date: February 13–14, 2025. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 9609 Medical Center Drive, Bethesda, 

MD 20892 (Virtual). 

Contact Person: Alumit Ishai, Ph.D., 

Scientific Review Officer, Office of Grants 

Management and Scientific Review, National 

Center for Advancing Translational Sciences, 

National Institutes of Health, 9609 Medical 

Center Drive, Suite 1E504, Bethesda, MD 

20892, (301) 827–5819, alumit.ishai@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: November 14, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–27046 Filed 11–19–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting. 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


khammond on DSK9W7S144PROD with NOTICES
Federal Register / Vol. 89, No. 224 / Wednesday, November 20, 2024 / Notices 91775 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Clinical Trial Readiness 

Review Meeting. 

Date: December 13, 2024. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Meeting Format: Virtual Meeting. 

Contact Person: Ana Olariu, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH/DHHS, NSC, 6001 Executive 

Boulevard, Rockville, MD 20852, 301–496– 

9223 Ana.Olariu@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS). 

Dated: November 14, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–27047 Filed 11–19–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–0361. 

Project: Zero Suicide in Health Systems 

Evaluation—New Package 

The Substance Abuse and Mental 

Health Services Administration 

(SAMHSA)’s Center for Mental Health 

Services (CMHS) is requesting clearance 

for the new data collection associated 

with the evaluation of the SAMHSA 

Zero Suicide in Health Systems (Zero 

Suicide Evaluation). The Zero Suicide 

program is authorized under the CURES 

Act. SAMHSA is required to evaluate 

the Zero Suicide grant, specifically (1) 

evaluate the activities supported by 

grants awarded, disseminate, as 

appropriate, the findings from the 

evaluation; and (2) provide appropriate 

information, training, and technical 

assistance, as appropriate, to eligible 

entities that receive a grant under this 

section, in order to help such entities to 

meet the requirements of this section, 

including assistance with selection and 

implementation of evidence. 

The goal of the Zero Suicide program 

is the reduction of suicide and suicide 

attempts across America, focusing on 

individuals who are 25 years and older. 

The purpose of this program is to 

implement the Zero Suicide 

intervention and prevention model for 

adults throughout a health system or 

systems. The Zero Suicide model is a 

comprehensive, multi-setting approach 

to suicide prevention in health systems. 

To accomplish this critical, lifesaving 

work, it is essential that the 

effectiveness of these programs be 

evaluated on an ongoing basis, with 

implementation of suicide prevention 

programs continually informed by highquality evaluation results. SAMHSA 

will use this data to reduce suicide 

ideation, suicide attempts, and deaths 

due to suicide. 

SAMHSA has awarded new grants 

and continued funding to 25 grantees, 

Cohort 5 (15 grantees) with project 

period of Sept 30, 2023, to Sept 29, 

2028; and Cohort 4 (10 grantees; 

includes one tribal organization) with 

project period of March 31, 2021, to 

March 30, 2026. SAMHSA has 

requested funding for 11 grantees to be 

funded as Cohort 6 in the fiscal year 

2025. 

The Zero Suicide Evaluation is 

designed to evaluate the 

implementation, effectiveness, and 

overall impact of the Zero Suicide 

program upon grantees in the United 

States. The evaluation will assess Zero 

Suicide program activities implemented 

by grantees and ultimately provide 

SAMHSA with the information needed 

to understand and document program 

effectiveness on reducing suicide 

morbidity and mortality, specifically 

among those who encounter the 

healthcare system. While 

acknowledging the lack of evidence for 

cultural adaptations to evidence-based 

and empirically supported treatments 

and interventions, and that research has 

not been conducted with historically 

marginalized and underserved 

communities (e.g., Black, Asian, 

Autistic, Lesbian, Gay, Bisexual, 

Transgender, Queer, Intersex, and 

Asexual Plus (LGBTQIA+), and others), 

Zero Suicide pushes systems to ensure 

that clients’ cultural contexts are 

considered and honored in what 

treatments are offered and how those 

treatments are adapted. Thus, with 

behavioral health equity as a central 

component woven throughout the Zero 

Suicide Framework, the proposed 

evaluation will ensure that each study 

includes specific behavioral health 

equity tenets to ensure a culturally 

specific understanding of Zero Suicide 

implementation, outcomes, and 

impacts. 

The Zero Suicide Evaluation includes 

four studies: Systems Change, Work 

Force, Consumer Experience, and 

Impact. The purpose of the Systems 

Change Study is to understand how 

grantees are implementing the Zero 

Suicide Program. The Systems Change 

Study collection instruments include 

the: Prevention Strategies Inventory 

(PSI), Behavioral Health Provider 

Survey (BHPS), Case Studies, and Cost 

Sub-Studies. 

The purpose of the Workforce Study 

is to document staff awareness and 

perceptions associated with the Zero 

Suicide activities implemented by Zero 

Suicide-participating Healthcare 

Organizations (HCOs). The Workforce 

Study instruments include the: Work 

Force Survey (WFS), Training Activity 

Summary Page (TASP), and the Training 

Utilization and Preservation Survey 

(TUPS). 

The purpose of Consumer Experience 

Study is to understand the relationship 

between Zero Suicide activities and key 

clinical outcomes (i.e., suicide risk, 

depression), along with consumer 

perceptions of care, access to care, 

services received, and treatment 

adherence. The Consumer Experience 

Study instruments include the: BHPS, 

Consumer Experience Survey (CES), 

Clinical Outcomes Form (COF), and 

Grantee Performance Data. 

The Impact Study will use secondary 

data and quasi-experimental designs to 

develop a control group and estimate 

the causal impact of the Zero Suicide 

Program on suicide morbidity and 

mortality. 

Ultimately, the purpose of the Zero 

Suicide Evaluation is to build the 

program’s knowledge base of 

effectiveness by thoroughly describing 

the implementation, outcomes, and 

impact of a program meant to reduce 

deaths by suicide. 

The total annualized burden is an 

estimated 15,504 respondents for the 

Zero Suicide instruments, with a 

combined hourly estimate to be 4,902 

hours. Burden estimates are based on 

the data collection requirements and the 

number of respondents. The estimated 

response burden to collect this 

information associated with the Zero 

Suicide Evaluation annualized over the 

requested 3-year clearance period is 

presented below: 


khammond on DSK9W7S144PROD with NOTICES